Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure

Journal of Infectious Diseases

Volumn 201, Issue 5, 2010, Pages 662-671

  Paredes, Roger ^a,c   Lalama, Christina M ^b   Ribaudo, Heather J ^b   Schackman, Bruce R ^e   Shikuma, Cecilia ^e   Gigue, Francoise ^a   Meyer III, William A ^f   Johnson, Victoria A ^g,h   Fiscus, Susan A ⁱ   D'Aquila, Richard T ^j   Gulick, Roy M ^d   Kuritzkes, Daniel R ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e UNIVERSITY OF HAWAII   (United States)

^f QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

^g BIRMINGHAM VA MEDICAL CENTER   (United States)

^h UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

ⁱ UNIVERSITY OF NORTH CAROLINA   (United States)

^j VANDERBILT UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GENETIC VARIABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; TREATMENT FAILURE; VIRUS GENE; VIRUS MUTANT; VIRUS MUTATION;

ADULT; AMINO ACID SUBSTITUTION; ANTI-HIV AGENTS; BENZOXAZINES; CASE-CONTROL STUDIES; COHORT STUDIES; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MUTATION, MISSENSE; POLYMERASE CHAIN REACTION; TREATMENT FAILURE;

EID: 76449101531     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/650543     Document Type: Article

References (34)

1. Hammer SM, Eron JJ Jr, Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society- USA panel. JAMA 2008; 300:555-570.
2. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. http://aidsinfo.nih.gov/contentfiles/Adultand AdolescentGL.pdf. Updated 29 January 2008. Accessed 10 February 2008.
3. Hirsch MS, Gunthard HF, Schapiro JM, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis 2008; 47:266-285.
4. Kozal MJ, Hullsiek KH, Macarthur RD, et al. The incidence of HIV drug resistance and its impact on progression of HIV disease among antiretroviral-naive participants started on three different antiretroviral therapy strategies. HIV Clin Trials 2007; 8:357-370.
5. Kuritzkes DR, Lalama CM, Ribaudo HJ, et al. Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects. J Infect Dis 2008; 197:867-870.
6. Sax PE, Islam R, Walensky RP, et al. Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis. Clin Infect Dis 2005; 41:1316-1323.
7. Vray M, Meynard JL, Dalban C, et al. Predictors of the virological response to a change in the antiretroviral treatment regimen in HIV- 1-infected patients enrolled in a randomized trial comparing genotyping, phenotyping and standard of care (Narval trial, ANRS 088). Antivir Ther 2003; 8:427-434.
8. Tural C, Ruiz L, Holtzer C, et al. Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. AIDS 2002; 16:209-218.
9. Baxter JD, Mayers DL, Wentworth DN, et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS 2000; 14:F83-F93.
10. Harrigan PR, Hertogs K, VerbiestW, et al. Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community setting. AIDS 1999; 13:1863-1871.
11. Brun-Vezinet F, Costagliola D, Khaled MA, et al. Clinically validated genotype analysis: guiding principles and statistical concerns. Antivir Ther 2004; 9:465-478.
12. Grant RM, Kuritzkes DR, Johnson VA, et al. Accuracy of the TRUGENE HIV-1 genotyping kit. J Clin Microbiol 2003; 41:1586-1593.
13. Margulies M, Egholm M, Altman WE, et al. Genome sequencing in microfabricated high-density picolitre reactors. Nature 2005; 437:376-380.
14. Paredes R, Marconi VC, Campbell TB, Kuritzkes DR. Systematic evaluation of allele-specific real-time PCR for the detection of minor HIV- 1 variants with pol and env resistance mutations. J Virol Methods 2007; 146:136-146.
15. Metzner KJ, Rauch P, Walter H, et al. Detection of minor populations of drug-resistant HIV-1 in acute seroconverters. AIDS 2005; 19:1819-1825.
16. Lecossier D, Shulman NS, Morand-Joubert L, et al. Detection of minority populations of HIV-1 expressing the K103N resistance mutation in patients failing nevirapine. J Acquir Immune Defic Syndr 2005; 38: 37-42.
17. Dykes C, Najjar J, Bosch RJ, et al. Detection of drug-resistant minority variants of HIV-1 during virologic failure of indinavir, lamivudine, and zidovudine. J Infect Dis 2004; 189:1091-1096.
18. Charpentier C, Dwyer DE, Mammano F, Lecossier D, Clavel F, Hance AJ. Role of minority populations of human immunodeficiency virus type 1 in the evolution of viral resistance to protease inhibitors. J Virol 2004; 78:4234-4247.
19. Palmer S, Boltz V, Martinson N, et al. Persistence of nevirapine-resistant HIV-1 in women after single-dose nevirapine therapy for prevention of maternal-to-fetal HIV-1 transmission. Proc Natl Acad Sci U S A 2006; 103:7094-7099.
20. Cai F, Chen H, Hicks CB, Bartlett JA, Zhu J, Gao F. Detection of minor drug-resistant populations by parallel allele-specific sequencing. Nat Methods 2007; 4:123-125.
21. Paredes R, Cheng I, Kuritzkes DR, Tuomala RE. High prevalence of primary lamivudine and nelfinavir resistance in HIV-1-infected pregnant women in the United States, 1998-2004. AIDS 2007; 21:2103-2106.
22. Simen BB, Simons JF, Hullsiek KH, et al. Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naïve patients significantly impact treatment outcomes. J Infect Dis 2009; 199(5):693-701.
23. Gulick RM, Ribaudo HJ, Shikuma CM, et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med 2004; 350:1850-1861.
24. Ribaudo HJ, Kuritzkes DR, Gulick RM. A comparison of three initial antiretroviral AIDS regimens. N Engl J Med 2007; 357:1056-1057.
25. Prentice RL. Opportunities for enhancing efficiency and reducing cost in large scale disease prevention trials: a statistical perspective. Stat Med 1990; 9:161-170; discussion, 170-172.
26. Chesney MA, Ickovics JR, Chambers DB, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee E` Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). AIDS Care 2000; 12:255-266.
27. Schackman BR, Ribaudo HJ, Krambrink A, Hughes V, Kuritzkes DR, Gulick RM. Racial differences in virologic failure associated with adherence and quality of life on efavirenz-containing regimens for initial HIV therapy: results of ACTG A5095. J Acquir Immune Defic Syndr 2007; 46:547-554.
28. Lin HJ, Tanwandee T, Hollinger FB. Improved methods for quantification of human immunodeficiency virus type 1 RNA and hepatitis C virus RNA in blood using spin column technology and chemiluminescent assays of PCR products. J Med Virol 1997; 51:56-63.
29. Barlow WE, Ichikawa L, Rosner D, Izumi S. Analysis of case-cohort designs. J Clin Epidemiol 1999; 52:1165-1172.
30. Havlir D, McLaughlin MM, Richman DD. A pilot study to evaluate the development of resistance to nevirapine in asymptomatic human immunodeficiency virus-infected patients with CD4 cell counts of 1500/ mm3: AIDS Clinical Trials Group Protocol 208. J Infect Dis 1995; 172: 1379-1383.
31. Havlir DV, Eastman S, Gamst A, Richman DD. Nevirapine-resistant human immunodeficiency virus: kinetics of replication and estimated prevalence in untreated patients. J Virol 1996; 70:7894-7899.
32. Richman DD, Havlir D, Corbeil J, et al. Nevirapine resistancemutations of human immunodeficiency virus type 1 selected during therapy. J Virol 1994; 68:1660-1666.
33. Johnson JA, Li JF, Wei X, et al. Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naive populations and associate with reduced treatment efficacy. PLoS Med 2008; 5:e158.
34. MacArthur RD, Novak RM, Peng G, et al. A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial. Lancet 2006; 368:2125-2135.